Idorsia Wins Inaugural Prix Galien Bridges Award For Its Innovative Insomnia Treatment In “Best Biotechnology & Pharmaceutical Product” Category

Idorsia Ltd has announced that its innovative treatment for insomnia disorder has received the inaugural Prix Galien Bridges Award in the category of “Best Biotechnology & Pharmaceutical Product.” This prestigious recognition celebrates breakthrough medicines—from biologics and gene therapies to advanced pharmaceutical compounds—that significantly elevate patient care through scientific excellence and innovation.

Bettina Blosse, General Manager of Idorsia Nordics, stated that the company is deeply honored to receive this award, especially as the first recipient in the Nordic region. She emphasized that the recognition reflects Idorsia’s commitment to developing meaningful healthcare solutions and highlights the value the new insomnia therapy brings to patients. Blosse added that her team is dedicated to ensuring that patients across the Nordic region gain access to this important medicine.

Martine Clozel, MD and Chief Scientific Officer, shared insights into the long and meticulous scientific journey behind the treatment. She explained that Idorsia began studying orexin and its receptors shortly after the system was first identified in 1998. Their early discoveries showed that blocking the orexin system could promote natural, physiologic sleep. With the goal of addressing insomnia disorder, the team set out to design a dual orexin receptor antagonist that would meet several demanding criteria, including rapid onset, sustained action throughout the night, and avoidance of morning drowsiness or residual effects.

Clozel noted that it took more than a decade of intensive work and the synthesis and evaluation of over 25,000 compounds to identify the final molecule—one that now stands honored by the Prix Galien Bridges Award. She emphasized that the treatment not only improves sleep quality for people with insomnia disorder but also has a meaningful impact on their daytime alertness and overall functioning. The award underscores the scientific rigor and dedication behind Idorsia’s research efforts and marks a significant achievement in advancing therapies for sleep-related health challenges.